|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM364667982 |
| 003 |
DE-627 |
| 005 |
20240114233817.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231226s2024 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1111/jfd.13883
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1256.xml
|
| 035 |
|
|
|a (DE-627)NLM364667982
|
| 035 |
|
|
|a (NLM)37975241
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Jaramillo, D
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a New Zealand rickettsia-like organism and Tenacibaculum maritimum vaccine efficacy study
|
| 264 |
|
1 |
|c 2024
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 11.01.2024
|
| 500 |
|
|
|a Date Revised 11.01.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2023 John Wiley & Sons Ltd.
|
| 520 |
|
|
|a A cohort of Chinook salmon juveniles was vaccinated, with an autogenous bivalent vaccine against New Zealand RLOs (NZ-RLO1) and Tenacibaculum maritimum. A proportion of the cohort was not vaccinated to act as controls. At smoltification, the fish were challenged with NZ-RLO1, NZ-RLO2, or T. maritimum. We found that challenge with T. maritimum by immersion in (7.5 × 105 cfu/mL of water) did not yield any pathology. Challenge with RLOs produced clinical signs that were more or less severe depending on the challenge route, dose or vaccination status. Survival was significantly higher for vaccinated fish within the groups challenged with NZ-RLO1 by intraperitoneal injection with a relative percent survival (RPS) of 48.84%. Survival was not significantly different between vaccinated and non-vaccinated fish for groups challenged with NZ-RLO2 by intraperitoneal injection or by NZ-RLO1 by immersion. Yet, anecdotally the clinical disease presentation (manifesting as haemorrhagic, ulcerative skin lesions) was more severe for the non-vaccinated fish. This study demonstrates that autogenous vaccine against NZ-RLO is protective against severe disease and death by NZ-RLO1 challenge which warrants implementation and further evaluation under field conditions. Yet, this study also highlights the importance of the route of administration and dose when evaluating pathogenicity and vaccine efficacy
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Piscirickettsia
|
| 650 |
|
4 |
|a Tenacibaculum maritimum
|
| 650 |
|
4 |
|a Rickettsia-like organisms
|
| 650 |
|
4 |
|a salmon
|
| 650 |
|
4 |
|a vaccine
|
| 700 |
1 |
|
|a Busby, B P
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Bestbier, M
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Bennett, P
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Waddington, Z
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Journal of fish diseases
|d 1998
|g 47(2024), 2 vom: 03. Jan., Seite e13883
|w (DE-627)NLM098166034
|x 1365-2761
|7 nnns
|
| 773 |
1 |
8 |
|g volume:47
|g year:2024
|g number:2
|g day:03
|g month:01
|g pages:e13883
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1111/jfd.13883
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 47
|j 2024
|e 2
|b 03
|c 01
|h e13883
|